ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,460.48
      -0.41%
      US Tech 100
      19,181.60
      -0.43%
      Dow Jones
      39,118.86
      -0.12%
      Brent Oil
      84.85
      0.00%
      Bitcoin
      61,611.25
      1.18%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. (MM) (DRTX)

      7. (MM) (DRTX) News

      DRTX

      (MM) (DRTX)

      (MM)
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:DRTX
      DateTimeSourceHeadlineSymbolCompany
      03/14/20147:32AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:DRTX(MM)
      03/14/20147:00AMGlobeNewswire Inc.Durata Therapeutics, Inc. Reports Fourth Quarter and Full-Year 2013 Financial ResultsNASDAQ:DRTX(MM)
      03/07/20148:00AMGlobeNewswire Inc.Durata Therapeutics to Announce Full Year 2013 Financial Results on March 14, 2014NASDAQ:DRTX(MM)
      03/03/20148:00AMGlobeNewswire Inc.Durata Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:DRTX(MM)
      02/18/20148:00AMGlobeNewswire Inc.Durata Therapeutics to Present at the RBC Capital Markets' Global Healthcare ConferenceNASDAQ:DRTX(MM)
      02/14/20149:27AMEdgar (US Regulatory)Schedule 13gNASDAQ:DRTX(MM)
      02/13/20145:27PMEdgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:DRTX(MM)
      02/13/20141:57PMEdgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:DRTX(MM)
      12/27/20137:00PMZacksDurata Progresses with Dalbavancin - Analyst BlogNASDAQ:DRTX(MM)
      12/23/20138:00AMGlobeNewswire Inc.European Medicines Agency Accepts Marketing Authorization Application for DalbavancinNASDAQ:DRTX(MM)
      12/03/20138:00AMGlobeNewswire Inc.Durata Therapeutics Submits Marketing Authorization Application for DalbavancinNASDAQ:DRTX(MM)
      11/26/20134:15PMGlobeNewswire Inc.Durata Therapeutics Announces FDA's Acceptance for Priority Review of NDA for Dalvance(TM) (dalbavancin hydrochloride)NASDAQ:DRTX(MM)
      11/15/20134:00PMGlobeNewswire Inc.Durata Therapeutics to Present at the Jefferies 2013 Global Healthcare ConferenceNASDAQ:DRTX(MM)
      11/15/20138:18AMDow Jones NewsFarallon Capital Management 3Q 13F: Largest EliminationsNASDAQ:DRTX(MM)
      11/15/20138:18AMDow Jones NewsFarallon Capital Management 3Q 13F: Holdings As Of Sep 30NASDAQ:DRTX(MM)
      11/06/20137:30AMPR Newswire (US)PDL BioPharma Provides $70 Million in Financing to Durata TherapeuticsNASDAQ:DRTX(MM)
      11/06/20136:46AMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:DRTX(MM)
      11/06/20136:36AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:DRTX(MM)
      11/06/20136:00AMGlobeNewswire Inc.Durata Therapeutics, Inc. Reports Third Quarter 2013 Financial ResultsNASDAQ:DRTX(MM)
      11/05/20137:30AMGlobeNewswire Inc.Durata Therapeutics to Present at the 2013 Credit Suisse Healthcare ConferenceNASDAQ:DRTX(MM)
      10/30/20137:30AMGlobeNewswire Inc.Durata Therapeutics to Announce Third Quarter 2013 Financial Results on November 6, 2013NASDAQ:DRTX(MM)
      10/02/20137:30AMGlobeNewswire Inc.Durata Therapeutics Presents New Comprehensive Review of the Efficacy and Safety Data of Dalbavancin and New In Vitro Finding...NASDAQ:DRTX(MM)
      09/26/20132:48PMGlobeNewswire Inc.Durata Therapeutics Announces NDA Submission for Dalbavancin for the Treatment of Patients With Acute Bacterial Skin and Skin...NASDAQ:DRTX(MM)
      09/25/20137:30AMGlobeNewswire Inc.Dalbavancin Study Results to be Presented at IDWeek 2013NASDAQ:DRTX(MM)
      09/10/20133:12PMGlobeNewswire Inc.Durata Therapeutics Presents New Pivotal Phase 3 Clinical Results and New In Vitro Data on Dalbavancin at ICAACNASDAQ:DRTX(MM)
      09/03/20133:03PMGlobeNewswire Inc.Dalbavancin Study Results to be Presented in Three Posters at the 53rd Annual ICAAC MeetingNASDAQ:DRTX(MM)
      08/07/20138:07AMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:DRTX(MM)
      08/07/20138:02AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:DRTX(MM)
      08/07/20137:30AMGlobeNewswire Inc.Durata Therapeutics, Inc. Reports Second Quarter 2013 Financial ResultsNASDAQ:DRTX(MM)
      08/06/20137:30AMGlobeNewswire Inc.Durata Therapeutics to Present at the 2013 Wedbush Securities Life Sciences Management Access ConferenceNASDAQ:DRTX(MM)
       Showing the most relevant articles for your search:NASDAQ:DRTX